Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Real-world data in guiding amyloidosis treatment

Ashutosh Wechalekar • 31 May 2020
Amyloidosis Rare Diseases Bortezomib Cyclophosphamide Dexamethasone

Ashutosh Wechalekar, MBBS, FRCP, FRCPath, of the University College London Hospitals NHS Trust, London, UK, addresses the significance of real-world data for amyloidosis treatment. Here, Dr Wechalekar discusses how real-world examples and data can guide treatment outside of a trial setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Ashutosh Wechalekar

9:53
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Ashutosh Wechalekar et al. • 9 Dec 2023
0:54
The potential of daratumumab alone or with CyBorD in patients with stage IV AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
1:07
The safety and efficacy of belantamab mafodotin in AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
2:14
Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges
Ashutosh Wechalekar • 12 Dec 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals